ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.
|Articles|July 17, 2023
Eleven Therapeutics, Novo Nordisk Reveal Nucleic Acid Therapy Collaboration
Companies aim to discover novel molecules that promote precise delivery of nucleic acid.
Advertisement
Eleven Therapeutics, a biotechnology company focusing on developing RNA therapeutics through the combination of chemistry and artificial intelligence, has officially announced a research collaboration with Novo Nordisk. According to the biotech, the companies intend to leverage Eleven’s DELiveri™ platform to discover novel molecules that promote precise delivery of nucleic acid.
"Our research collaboration with Eleven Therapeutics builds on Novo Nordisk's commitment to advancing precision medicine and opens up the opportunity to learn from one another as we explore novel cell-specific targeting strategies,” said Uli Stilz, head, bio innovation hub, Novo Nordisk, in a press release. “With the combination of our joint team's expertise and using Eleven's DELiveri™ platform, we can potentially unlock transformative treatments for people living with cardiometabolic diseases."
Reference: Eleven Therapeutics Announces Research Collaboration with Novo Nordisk to Discover Cell-Specific Carriers of Nucleic Acid Therapeutics. PR Newswire. July 17, 2023. Accessed July 17, 2023. https://www.prnewswire.com/news-releases/eleven-therapeutics-announces-research-collaboration-with-novo-nordisk-to-discover-cell-specific-carriers-of-nucleic-acid-therapeutics-301878265.html
Advertisement
Related to this article
Dr. Brian Corgiat makes the case for phosphoproteome testing—measuring what’s actively driving a tumor right now, not just static mutations.
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel disease to AbbVie for up to $1.37 billion.
Ignite Proteomics’ Dr. Brian Corgiat explains why tumors change over time—and why treatment must adapt to the current tumor, not the original.
Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.
Lonza will add bioconjugate, payload-linker and viral vector capacity and about 1,100 employees; closing is expected in mid-2027.
Advertisement
Advertisement
Trending on PharmExec
1
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
2
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
3
Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie
4
How Tumors Change Over Time, and How This Impacts Treatment
5